發(fā)布時(shí)間：2018-12-16 12:18

【摘要】：目的采用循證醫(yī)學(xué)的方法,系統(tǒng)評(píng)價(jià)參苓白術(shù)散聯(lián)合西藥治療潰瘍性結(jié)腸炎的臨床療效,科學(xué)了解目前的治療狀況,為今后臨床治療潰瘍性結(jié)腸炎提供科學(xué)的參考價(jià)值。方法計(jì)算機(jī)檢索中國(guó)知網(wǎng)(1982-2015)、萬(wàn)方(2001-2015)、維普(1989-2015)、讀秀(1996-2015)、PUBMED(1991-2015)、PLoS公共醫(yī)學(xué)科學(xué)圖書(shū)館(1991-2015)、PMC美國(guó)國(guó)家醫(yī)學(xué)圖書(shū)館生命科學(xué)期刊(1991-2015)等數(shù)據(jù)庫(kù),收集有關(guān)參苓白術(shù)散聯(lián)合西藥治療潰瘍性結(jié)腸炎的臨床隨機(jī)對(duì)照試驗(yàn)(RCT),由2位評(píng)價(jià)者按照Cochrane系統(tǒng)評(píng)價(jià)方法,從隨機(jī)方法、盲法的運(yùn)用、樣本含量、治療方法、統(tǒng)計(jì)學(xué)方法、隨訪與失訪等內(nèi)容獨(dú)立地進(jìn)行文獻(xiàn)的篩選、資料提取與質(zhì)量評(píng)價(jià),采用RevMan5.3統(tǒng)計(jì)軟件進(jìn)行Meta分析。結(jié)果初檢出相關(guān)文獻(xiàn)558篇,剔除重復(fù)發(fā)表及無(wú)數(shù)據(jù)可用的文獻(xiàn)后獲得185篇。通過(guò)閱讀標(biāo)題和摘要及全文,最終納入10篇進(jìn)入meta分析,共884例,其中治療組(口服參苓白術(shù)散聯(lián)合西藥治療)447例,對(duì)照組(口服常規(guī)西藥治療)437例。10個(gè)研究的總有效率、顯效率、無(wú)效率研究異質(zhì)性不明顯,采用固定效應(yīng)模型進(jìn)行Meta分析,參苓白術(shù)散聯(lián)合西藥組在治療潰瘍性結(jié)腸炎的總有效率[OR=3.30,95%CI(2.25,4.82),P0.01]、顯效率[OR=2.02,95%CI(1.54,2.65),P0.01]均優(yōu)于對(duì)照組,有效率與對(duì)照組相近[OR=1.08,95%CI(0.78,1.50),P=0.64],無(wú)效率則低于對(duì)照組[OR=0.30,95%CI(0.21,0.44),P0.01],差異有顯著統(tǒng)計(jì)學(xué)意義;1個(gè)研究進(jìn)行了復(fù)發(fā)率比較,治療組復(fù)發(fā)率19.4%;對(duì)照組復(fù)發(fā)率50.0%,兩組比較有顯著性差異(χ2=5.35,P0.05)。漏斗圖分析不對(duì)稱,表明存在發(fā)表性偏倚。結(jié)論參苓白術(shù)散聯(lián)合西藥療法治療潰瘍性結(jié)腸炎的療效與常規(guī)西藥療法相比,具有療效優(yōu)勢(shì)。受納入研究質(zhì)量與數(shù)量限制,因此上述結(jié)論仍待更多高質(zhì)量、大樣本的臨床隨機(jī)對(duì)照研究進(jìn)一步驗(yàn)證。
[Abstract]:Objective to evaluate the clinical effect of Shenling Atractylodes Powder combined with western medicine in the treatment of ulcerative colitis by using the method of evidence-based medicine, to scientifically understand the current treatment situation and to provide scientific reference value for clinical treatment of ulcerative colitis in the future. Methods A computer search was conducted on China Zhiwang (1982-2015), Wanfang (2001-2015), Weipu (1989-2015), PLoS (1996-2015), PUBMED (1991-2015) and), PLoS Public Medical Science Library (1991-2015). PMC National Library of Medical Sciences Journal of Life Sciences (1991-2015) and other databases collected the clinical randomized controlled trial (RCT),) related to the treatment of ulcerative colitis with Shenling Atractylodes powder combined with western medicine. Two evaluators evaluated (RCT), according to the Cochrane system. The random method, blind method, sample size, treatment method, statistical method, follow-up and lost visit were used to screen the literature, extract the data and evaluate the quality independently. The Meta analysis was carried out by RevMan5.3 statistical software. Results A total of 558 literatures were initially identified, and 185 articles were obtained after repeated publication and no data were available. By reading the title, abstract and full text, 10 articles were included in the meta analysis, including 447 cases in the treatment group (oral Shenling Baizhu Powder combined with western medicine). In the control group, 437 cases were treated by oral routine western medicine. The total effective rate, and inefficiency of 10 studies were not obvious. The fixed effect model was used for Meta analysis. The total effective rate [OR=3.30,95%CI (2.254.82), P0.01] and the effective rate [OR=2.02,95%CI (1.54 鹵2.65), P0.01] of Shenling Baizhu Powder combined with western medicine group were better than those of the control group. The effective rate was similar to that of the control group [OR=1.08,95%CI (0.78U 1.50), P < 0.64], but the ineffective rate was lower than that of the control group [OR=0.30,95%CI (0.21 鹵0.44), P0.01]. The difference was statistically significant. In one study, the recurrence rate was 19.4g in the treatment group and 50.0 in the control group. There was a significant difference between the two groups (蠂 2, 5.35, P0.05). The analysis of asymmetry by funnel graph indicates that there is a published bias. Conclusion the curative effect of Shenling Baizhu Powder combined with western medicine in the treatment of ulcerative colitis is superior to that of routine western medicine. Limited by the quality and quantity of the included studies, the above conclusions need to be further verified in a large sample of randomized controlled clinical trials with more high quality.
【學(xué)位授予單位】：湖北中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R574.62

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 張雪;;參苓白術(shù)散加減配合中藥保留灌腸治療脾胃虛弱型潰瘍型結(jié)腸炎療效觀察[J];遼寧中醫(yī)藥大學(xué)學(xué)報(bào);2017年03期

2 梁海雄;黃家興;;藥物灌腸聯(lián)合中藥熱敷治療潰瘍性結(jié)腸炎臨床觀察[J];基層醫(yī)學(xué)論壇;2017年02期

3 李姿慧;王鍵;蔡榮林;劉曉麗;蔣懷周;;參苓白術(shù)散通過(guò)ERK/p38 MAPK信號(hào)通路干預(yù)潰瘍性結(jié)腸炎大鼠結(jié)腸組織AQP3、AQP4的表達(dá)[J];中成藥;2015年09期

4 馬光志;張曉祥;周彬;左秀然;聶慶華;;大數(shù)據(jù)時(shí)代的循證醫(yī)學(xué)[J];世界復(fù)合醫(yī)學(xué);2015年02期

5 李姿慧;王鍵;蔡榮林;孫娟;葉銘鋼;;參苓白術(shù)散對(duì)脾虛濕困型潰瘍性結(jié)腸炎大鼠結(jié)腸組織NF-κB p65蛋白表達(dá)及相關(guān)炎性因子的影響[J];北京中醫(yī)藥大學(xué)學(xué)報(bào);2015年05期

6 陳建科;;中藥保留灌腸治療潰瘍性結(jié)腸炎臨床研究[J];中醫(yī)學(xué)報(bào);2015年05期

7 馬惠紅;秦艷;王立紅;;參苓白術(shù)散合艾迪莎治療潰瘍性結(jié)腸炎療效觀察及對(duì)炎癥相關(guān)因子的影響[J];中醫(yī)藥導(dǎo)報(bào);2015年04期

8 劉玉暉;胡婕;易文鳳;游宇;;參苓白術(shù)散治療炎癥性腸病與腸上皮細(xì)胞緊密連接的關(guān)系探討[J];中國(guó)實(shí)驗(yàn)方劑學(xué)雜志;2015年03期

9 周全魁;龔杰;;美沙拉嗪和柳氮磺吡啶對(duì)潰瘍性結(jié)腸炎患者腸黏膜中TLR4和NF-κb表達(dá)的影響[J];中國(guó)現(xiàn)代醫(yī)學(xué)雜志;2015年01期

10 羅敏;李帥軍;胡響當(dāng);王曉艷;林仁敬;楊周雨;;芍藥湯對(duì)胃腸濕熱型潰瘍性結(jié)腸炎大鼠結(jié)腸黏膜核因子-κB DNA結(jié)合活性的影響[J];中國(guó)醫(yī)藥導(dǎo)報(bào);2015年03期

相關(guān)博士學(xué)位論文 前1條

1 王鵬;潰瘍性結(jié)腸炎的中醫(yī)證候?qū)W研究[D];北京中醫(yī)藥大學(xué);2014年

相關(guān)碩士學(xué)位論文 前5條

1 李冰;溫針灸治療潰瘍性結(jié)腸炎的臨床觀察[D];黑龍江省中醫(yī)藥科學(xué)院;2016年

2 林小常;芍藥湯調(diào)控炎癥因子改善EMT防治結(jié)腸炎相關(guān)癌的機(jī)制研究[D];南方醫(yī)科大學(xué);2015年

3 張曉婧;四神丸對(duì)潰瘍性結(jié)腸炎模型大鼠Foxp3、IL-23、IL-27的影響[D];甘肅中醫(yī)學(xué)院;2014年

4 馬丹;潰瘍性結(jié)腸炎中醫(yī)藥治療的回顧性研究[D];北京中醫(yī)藥大學(xué);2013年

5 張緒光;潰瘍性結(jié)腸炎診斷及治療的臨床觀察[D];山東大學(xué);2011年

，

本文編號(hào)：2382327